Join to View Full Profile
1100 9th AveVirginia Mason Med Ctr, Div Hem/OncSeattle, WA 98101
Phone+1 206-223-6600
Dr. Picozzi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1981 - 1982
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
Stanford University School of MedicineClass of 1978
Certifications & Licensure
CA State Medical License 1981 - Present
WA State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer Start of enrollment: 2003 Mar 01
- Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT Start of enrollment: 2008 Sep 01
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana, Bohuslav Melichar, Anup Kasi
Journal of Clinical Oncology. 2025-07-20 - Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study.Vincent J Picozzi, Margaret T Mandelson, Anas Najjar, Moming Li, Diala E Harb
The Oncologist. 2025-04-04 - Treatment of advanced pancreatic cancer: When will the third time be a charm?Vincent J Picozzi
Cancer. 2024-11-01
Journal Articles
- Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor InitiativeSameh Mikhail, Vincent J Picozzi, Clinical Cancer Research
Lectures
- Prognostic value (PV) of pathologic response (PR) to neoadjuvant chemotherapy (NC) alone in resected pancreatic cancer (PDAC): Initial analysis.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 cl...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Research Spotlight by Dr. Anna Berkenblit: June 2025June 23rd, 2025- 'I Won't Hold My Breath': What We Heard This WeekJune 8th, 2025
- Survival in Unresectable Pancreatic Cancer Improved with Tumor Treating FieldsJune 2nd, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
